; Overactive Bladder - Pipeline Review, H2 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Overactive Bladder - Pipeline Review, H2 2011

VIEWS: 11 PAGES: 101

Overactive Bladder - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H2 2011', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Overactive Bladder. 'Overactive Bladder - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Overactive Bladder. - A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Overactive Bladder pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Overactive Bladder. - Identify emerging players with potentially strong product portfolio and desig

More Info
  • pg 1
									Overactive Bladder – Pipeline Review, H2 2011




              Overactive Bladder - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1474IDB

                                                                                          Publication Date: October 2011




Overactive Bladder – Pipeline Review, H2 2011                                                                    GMDHC1474IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Overactive Bladder – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 7
      List of Figures .................................................................................................................................................................................................... 8
Introduction .............................................................................................................................................................................................................. 9
      Global Markets Direct Report Coverage ............................................................................................................................................................. 9
Overactive Bladder Overview ..................................................................................................................................................................................10
Therapeutics Development ......................................................................................................................................................................................11
      An Overview of Pipeline Products for Overactive Bladder .................................................................................................................................11
Overactive Bladder Therapeutics under Development by Companies ......................................................................................................................13
Overactive Bladder Therapeutics under Investigation by Universities/Institutes .......................................................................................................15
Late Stage Products ................................................................................................................................................................................................16
      Comparative Analysis .......................................................................................................................................................................................16
Mid Clinical Stage Products .....................................................................................................................................................................................17
      Comparative Analysis .......................................................................................................................................................................................17
Early Clinical Stage Products ..................................................................................................................................................................................18
      Comparative Analysis .......................................................................................................................................................................................18
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................19
      Comparative Analysis .......................................................................................................................................................................................19
Overactive Bladder Therapeutics - Products under Development by Companies .....................................................................................................20
Overactive Bladder Therapeutics - Products under Investigation by Universities/Institutes ......................................................................................23
Companies Involved in Overactive Bladder Therapeutics Development ..................................................................................................................24
      Allergan, Inc. .....................................................................................................................................................................................................24
      Antares Pharma, Inc. ........................................................................................................................................................................................24
      Dainippon Sumitomo Pharma Co., Ltd. .............................................................................................................................................................25
      American Oriental Bioengineering, Inc. .............................................................................................................................................................25
      Astellas Pharma Inc. .........................................................................................................................................................................................26
      Auxilium Pharmaceuticals, Inc...........................................................................................................................................................................26
      Japan Tobacco Inc. ...........................................................................................................................................................................................27
      Kissei Pharmaceutical Co., Ltd. .........................................................................................................................................................................27
      Ono Pharmaceutical Co., Ltd. ...........................................................................................................................................................................28
      Pfizer Inc. ..........................................................................................................................................................................................................28
      Recordati S.p.A. ................................................................................................................................................................................................29
      Teva Pharmaceutical Industries Limited ............................................................................................................................................................29
      Merck KGaA......................................................................................................................................................................................................30
      Hisamitsu Pharmaceutical Co., Inc. ...................................................................................................................................................................30
      Urigen Pharmaceuticals, Inc..............................................................................................................................................................................31
      Plethora Solutions Holdings plc .........................................................................................................................................................................31
      KeyNeurotek Pharmaceuticals AG ....................................................................................................................................................................32
      Respiratorius AB ...............................................................................................................................................................................................32
      PharmEste ........................................................................................................................................................................................................33
      Hydra Biosciences, Inc. .....................................................................................................................................................................................33
      Mt Cook Pharma. Inc. .......................................................................................................................................................................................34
      Ion Channel Innovations, LLC ...........................................................................................................................................................................34
Overactive Bladder - Therapeutics Assessment ......................................................................................................................................................35
      Assessment by Monotherapy Products .............................................................................................................................................................35
      Assessment by Combination Products ..............................................................................................................................................................36
      Assessment by Route of Administration ............................................................................................................................................................37


Overactive Bladder – Pipeline Review, H2 2011                                                                                                                  GMDHC1474IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                 Page(2)
Overactive Bladder – Pipeline Review, H2 2011


      Assessment by Molecule Type ..........................................................................................................................................................................39
Drug Profiles ...........................................................................................................................................................................................................41
      SMP-986 - Drug Profile .....................................................................................................................................................................................41
            Product Description ....................................................................................................................................................................................41
            Mechanism of Action...................................................................................................................................................................................41
            R&D Progress .............................................................................................................................................................................................41
      ASP3652 - Drug Profile .....................................................................................................................................................................................42
            Product Description ....................................................................................................................................................................................42
            Mechanism of Action...................................................................................................................................................................................42
            R&D Progress .............................................................................................................................................................................................42
      YM905 - Drug Profile.........................................................................................................................................................................................43
            Product Description ....................................................................................................................................................................................43
            Mechanism of Action...................................................................................................................................................................................43
            R&D Progress .............................................................................................................................................................................................43
      Betanis - Drug Profile ........................................................................................................................................................................................44
            Product Description ....................................................................................................................................................................................44
            Mechanism of Action...................................................................................................................................................................................44
            R&D Progress .............................................................................................................................................................................................44
      UK-369003 - Drug Profile ..................................................................................................................................................................................45
            Product Description ....................................................................................................................................................................................45
            Mechanism of Action...................................................................................................................................................................................45
            R&D Progress .............................................................................................................................................................................................45
      AA4010 - Drug Profile .......................................................................................................................................................................................46
            Product Description ....................................................................................................................................................................................46
            Mechanism of Action...................................................................................................................................................................................46
            R&D Progress .............................................................................................................................................................................................46
      Anturol - Drug Profile.........................................................................................................................................................................................47
            Product Description ....................................................................................................................................................................................47
            Mechanism of Action...................................................................................................................................................................................47
            R&D Progress .............................................................................................................................................................................................47
      APT - Drug Profile .............................................................................................................................................................................................48
            Product Description ....................................................................................................................................................................................48
            Mechanism of Action...................................................................................................................................................................................48
            R&D Progress .............................................................................................................................................................................................48
      REC 0422 - Drug Profile....................................................................................................................................................................................49
            Product Description ....................................................................................................................................................................................49
            Mechanism of Action...................................................................................................................................................................................49
            R&D Progress .............................................................................................................................................................................................49
      REC 1819 - Drug Profile....................................................................................................................................................................................50
            Product Description ....................................................................................................................................................................................50
            Mechanism of Action...................................................................................................................................................................................50
            R&D Progress .............................................................................................................................................................................................50
      PSD506 - Drug Profile.......................................................................................................................................................................................51
            Product Description ....................................................................................................................................................................................51
            Mechanism of Action...................................................................................................................................................................................51
            R&D Progress .............................................................................................................................................................................................51
      URG302 - Drug Profile ......................................................................................................................................................................................53
            Product Description ....................................................................................................................................................................................53




Overactive Bladder – Pipeline Review, H2 2011                                                                                                                GMDHC1474IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                              Page(3)
Overactive Bladder – Pipeline Review, H2 2011


          Mechanism of Action...................................................................................................................................................................................53
          R&D Progress .............................................................................................................................................................................................53
     XEN-D0501 - Drug Profile .................................................................................................................................................................................54
          Product Description ....................................................................................................................................................................................54
          Mechanism of Action...................................................................................................................................................................................54
          R&D Progress .............................................................................................................................................................................................54
     JTS-653 - Drug Profile.......................................................................................................................................................................................55
          Product Description ....................................................................................................................................................................................55
          Mechanism of Action...................................................................................................................................................................................55
          R&D Progress .............................................................................................................................................................................................55
     KN203 - Drug Profile .........................................................................................................................................................................................56
          Product Description ....................................................................................................................................................................................56
          Mechanism of Action...................................................................................................................................................................................56
          R&D Progress .............................................................................................................................................................................................56
     MK-4618 - Drug Profile......................................................................................................................................................................................57
          Product Description ....................................................................................................................................................................................57
          Mechanism of Action...................................................................................................................................................................................57
          R&D Progress .............................................................................................................................................................................................57
     ONO-8539 - Drug Profile ...................................................................................................................................................................................58
          Product Description ....................................................................................................................................................................................58
          Mechanism of Action...................................................................................................................................................................................58
          R&D Progress .............................................................................................................................................................................................58
     ONO-8539 - Drug Profile ...................................................................................................................................................................................59
          Product Description ....................................................................................................................................................................................59
          Mechanism of Action...................................................................................................................................................................................59
          R&D Progress .............................................................................................................................................................................................59
     KUC-7483 - Drug Profile ...................................................................................................................................................................................60
          Product Description ....................................................................................................................................................................................60
          Mechanism o
								
To top